Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06037473
Other study ID # Gensci-LAGH-23003
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2023
Est. completion date August 1, 2029

Study information

Verified date September 2023
Source Beijing Children's Hospital
Contact Chunxiu Gong, Dr.
Phone 13370115001
Email chunxiugong@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.


Description:

A database registration study was developed to retrospectively analyze the efficacy and safety of polyethylene glycol recombinant human growth hormone injection in the treatment of slow growth in children caused by endogenous growth hormone deficiency, idiopathic short stature, Turner syndrome, etc., and to further prospectively follow up and monitor. In order to participate in the global real-world use of long-acting growth hormone, all data from this study were uploaded to the Global Registry of New Therapies for Rare Endocrine Diseases and Bone Disorders (GloBE-Reg) platform.


Recruitment information / eligibility

Status Recruiting
Enrollment 2600
Est. completion date August 1, 2029
Est. primary completion date January 1, 2029
Accepts healthy volunteers No
Gender All
Age group 14 Years to 18 Years
Eligibility Inclusion Criteria: Patients with endogenous growth hormone deficiency, Turner Syndrome, SGA, idiopathic short stature, etc. treated with polyethylene glycol recombinant human growth hormone injection Exclusion Criteria: Patients with serious heart and lung, blood system, malignant tumors and other diseases or systemic infections, immune function is low and Persons with mental illness;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Polyethylene glycol recombinant human growth hormone injection
0.1-0.3mg/kg.w

Locations

Country Name City State
China Department of Endocrinology, Genetics, Metabolism Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Beijing Children's Hospital Office for Rare Conditions Registries, University of Glasgow

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the change in height standard deviation score final adult height standard deviation score- height standard deviation score before treatment 3-10years
See also
  Status Clinical Trial Phase
Completed NCT01376921 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain N/A
Completed NCT01400997 - Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Czech Republic N/A
Completed NCT05244785 - Health and Nutrition Survey on Shenzhen Children
Completed NCT00097539 - A Postmarketing Surveillance Program for Nutropin, Nutropin AQ, and Protropin Phase 4
Not yet recruiting NCT04576845 - The Effect of Early Childhood Cow's Milk Allergy Elimination Diet on Eating Behaviors, Nutrition, and Growth Status
Not yet recruiting NCT05056285 - Pattern of Growth and Characteristics of Down Syndrome Pediatrics Patients
Completed NCT01263457 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK
Terminated NCT00330668 - Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency Phase 3
Completed NCT00378859 - The Effect of Milk and Meat on IGFs in Prepubertal Boys N/A
Not yet recruiting NCT05577130 - Growth Pattern and Characteristics of Cardiac Pediatric Patients
Recruiting NCT05033119 - PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics
Completed NCT01402999 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary N/A
Completed NCT01267526 - A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment N/A
Completed NCT00139451 - Nutrients and Hormones: Effects in Boys With Disordered Growth Phase 2
Terminated NCT03274973 - Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome
Completed NCT02015286 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East N/A
Completed NCT01582334 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina N/A
Completed NCT01439061 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Italy N/A
Completed NCT00125164 - Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency Phase 3
Completed NCT00174408 - Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age Phase 3